Paul G. Allen Frontiers Group    [to 16 Mar 2019]
No new digest content identified.

BMGF – Gates Foundation  [to 16 Mar 2019]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 16 Mar 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 16 Mar 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Germany joins CARB-X partnership in the fight against deadly drug-resistant superbugs
CARB-X announced today it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early development of antibiotics, vaccines, and diagnostics to combat drug-resistant bacteria. Under the agreement, BMBF will also provide an additional €1 million in direct support to a consortium of the German Center for Infection Research (DZIF), the Federal Institute for Vaccines and Biomedicines (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM), which is joining the CARB-X Global Accelerator Network, a network of 10 accelerators around the world to support CARB-X funded projects. CARB-X is a global non-profit partnership housed at Boston University.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 16 Mar 2019]
13 Mar 2019  Blog
The global economy is woefully unprepared for biological threats. This is what we need to do
EDCTP    [to 16 Mar 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news

13 March 2019
ASAAP clinical study of malaria treatment for children has started
A large clinical study evaluating a triple plus combination of antimalarials for children has started in Ghana. The study is coordinated by Dr. Oumou Maiga-Ascofare of the Kumasi Centre for Collaborative Research at the Kwame Nkrumah University of Science and…

Emory Vaccine Center    [to 16 Mar 2019]
No new digest content identified.
European Medicines Agency  [to 16 Mar 2019]
News and press releases
No new digest content identified.
European Vaccine Initiative  [to 16 Mar 2019]
Latest news
No new digest content identified.
FDA [to 16 Mar 2019]
March 14, 2019
Statement by FDA Commissioner Scott Gottlieb, M.D., on new strategies to modernize clinical trials to advance precision medicine, patient protections and more efficient product development

Modernizing clinical trials is an agency wide priority. As more diseases are being redefined based on genomic subtype, researchers have more novel targets and more opportunities to precisely modulate or even repair the basic biological drivers of illness. Precision guided medicines can demonstrate strong efficacy signals in early clinical trials, including in trials where small groups of patients are selected based on biomarkers or other criteria suggesting they’re likely to benefit. These trials can potentially allow earlier regulatory assessment of benefit and risk. When the agency can make a positive approval decision, patients can gain earlier access to important new therapeutic options. To take advantage of these innovations, the agency is also seeking new ways to modernize its approaches to accommodate these novel opportunities.

The FDA isn’t alone. The advent of precision medicine is challenging the entire medical research ecosystem to develop more efficient approaches to testing and developing diagnostics and therapeutics, to harness the full potential of science to reduce the suffering, death, and disability caused by complex human illnesses. The agency is committed to developing a regulatory framework for precision medicine that generates robust evidence of product safety and efficacy as efficiently as possible, including frameworks that are more carefully suited to the kinds of precision technologies that underpin new treatments.

But these opportunities can be delayed or stymied by a clinical research enterprise that is often extraordinarily complex and expensive. Efforts to streamline medical product development based on advancing science can be frustrated by legacy business models that discourage collaboration and data sharing, and the adoption of disruptive technologies that make clinical research more effective. Without a more agile clinical research enterprise capable of testing more therapies or combinations of therapies against an expanding array of targets more efficiently and at lower total cost, important therapeutic opportunities may be delayed or discarded because we can’t afford to run trials needed to validate them…

Fondation Merieux  [to 16 Mar 2019]
No new digest content identified.
Gavi [to 16 Mar 2019]
Latest News
Pneumoccocal vaccine price drops for third year running
In agreement with Gavi, Pfizer reduces price of pneumococcal vaccine to US$ 2.90 per dose for Gavi-eligible countries.
Geneva, 14 March 2019 – Pfizer has reduced the price of its pneumococcal vaccine (PCV) for 73 developing countries by five cents to US$ 2.90 per dose.

The price drop, a result of negotiations between Pfizer and Gavi, the Vaccine Alliance, is Pfizer’s third for its PCV vaccine since January 2017 and is expected to lead to savings to Gavi and developing country governments of US$ 4.1 million this year alone.

The reduction is the result of strong ongoing implementation of pneumococcal vaccine national programs and builds on efficiencies achieved through the introduction of the PCV four-dose vial (4-D MDV) as well as stable country volumes over the past three years. In 2017 the price of Pfizer’s PCV single dose vial (SDV) was US$ 3.30 per dose.

“Pneumonia remains the single largest cause of death for children worldwide and pneumococcal vaccine is one of our best weapons against it,” said Dr Seth Berkley, CEO of Gavi. “We have worked hard to boost access to this lifesaver in the world’s poorest countries – coverage rates in lower income, Gavi-eligible countries are now approaching the global average.  Lower prices, a result of our important partnership with Pfizer, have played a critical role in this effort…

Gavi and Zenysis Technologies to bring data and artificial intelligence to immunisation programmes

Geneva, 12 March 2019 – Gavi, the Vaccine Alliance and Zenysis Technologies, a Silicon Valley startup, have established a new strategic partnership that will help low-income countries harness the power of big data and artificial intelligence to improve childhood vaccination programs around the world.

Zenysis Technologies was identified by Gavi, through the INFUSE (Innovation for Uptake, Scale and Equity in Immunisation) yearly call for innovation. INFUSE aims to identify proven solutions which, when brought to scale, have the greatest potential to modernise global health and immunisation delivery.

A two-year partnership will provide countries with the Zenysis’ software platform, analytical training and IT skills development. Countries will use the platform’s capabilities to integrate data from their fragmented information systems and help decision-makers see where children are not receiving vaccines. Advanced analytics will then help countries decide how to target their limited resources for maximum impact.

“Weak immunisation data leads to poor planning, often meaning that children, whether they live in urban slums or remote rural outposts, miss out on lifesaving vaccines. Digital transformation of immunisation data and analytics is key to making sure that all children are protected from vaccine-preventable diseases,” said Gavi CEO Dr Seth Berkley. “Our partnership with Zenysis has the potential to increase efficiency and reduce costs for developing countries but, most importantly, it could save lives.”…
GHIT Fund   [to 16 Mar 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
Global Fund  [to 16 Mar 2019]
No new digest content identified.
Hilleman Laboratories   [to 16 Mar 2019]
No new digest content identified.
Human Vaccines Project   [to 16 Mar 2019]
No new digest content identified.
IAVI  [to 16 Mar 2019]
Iavi and partner scientific publications
March 12, 2019
Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda
PMID: 30857933
Abstract: Fisherfolks (FF) and female sex workers (FSW) in Uganda could be suitable key populations for HIV vaccine efficacy trials because of the high HIV incidence and good retention in observational cohorts. However, the observed HIV incidence may differ in participants who enroll into a trial. We used simulated vaccine efficacy trials (SiVET) nested within observational cohorts in these populations to evaluate this difference.
PMID Author: Abaasa A, Nash S, Mayanja Y, Price M, Fast PE, Kamali A, Kaleebu P, Todd J
No new digest content identified.
IFRC   [to 16 Mar 2019]
Press Releases 
Asia Pacific, Philippines
Millions of children at risk as death toll rises in Philippines measles outbreak
An estimated 3.7 million children under five in the Philippines are at risk during a measles outbreak that has already claimed 286 lives, most of them children or babies, the Red Cross is warning.
14 March 2019

Ukraine: Red Cross deployed to help contain largest measles outbreak in Europe in four years
Budapest/Geneva, 5 March 2019 – Ukrainian Red Cross Society volunteers are being deployed to help contain a measles outbreak that has affected more than 75,000 people, making it the largest outbreak in Europe since 2015.  This includes 54,000 measles c …
5 March 2019

IVAC  [to 16 Mar 2019]
No new digest content identified.

IVI   [to 16 Mar 2019]
IVI News & Announcements
No new digest content identified.
JEE Alliance  [to 16 Mar 2019]
Selected News and Events
Strategic Partnership for International Health Regulations (2005) and Health Security
12.3.2019   Article
The implementation of the International Health Regulations (2005) Monitoring and Evaluation Framework will draw on WHO’s convening role to facilitate strategic cooperation and generate collaborative…
MSF/Médecins Sans Frontières  [to 16 Mar 2019]
Selected News; Project Updates, Reports [as presented on website]
Conflict, curfew and floods put healthcare out of reach in Mopti
Project Update 12 Mar 2019
NIH  [to 16 Mar 2019]
No new digest content identified.
PATH  [to 16 Mar 2019]
March 11, 2019
Leading humanitarian, development, and global health organizations urge Congress to reject cuts to foreign assistance

Washington, D.C., March 11, 2019 — Leading humanitarian, development, and global health organizations Bread for the World, CARE, Catholic Relief Services, Interaction, International Rescue Committee, Mercy Corps, ONE, Oxfam, PATH, Save the Children, and World Vision, are calling on Members of Congress to protect the International Affairs budget in Fiscal Year 2020 (FY20) despite the Administration’s proposed 24 percent cuts. American leadership is critical in the face of daunting global challenges, from conflict to mass displacement, from food insecurity to global health crises.

More than 132 million people are projected to need humanitarian assistance in 2019 given an unprecedented number of humanitarian crises. Natural disasters, atrocities, gender-based violence, and protracted armed conflict have resulted in more than 68 million displaced persons, including more than 25 million refugees. Now is not the time to slash effective, life-saving programs that help create a safer and more secure world.

In addition, the Administration’s proposal to significantly modify and repeal the refugee mandate and resources of the Department of State’s humanitarian bureau, coupled with a 34 percent cut to humanitarian assistance, is unwise, especially given historic levels of displacement…

Sabin Vaccine Institute  [to 16 Mar 2019]
No new digest content identified.
UNAIDS [to 16 Mar 2019]
Selected Press Releases/Reports/Statements
11 March 2019
HIV prevention: not hitting the mark

The number of new HIV infections globally continues to fall. Modelled estimates show that new infections (all ages) declined from a peak of 3.4 million [2.6 million–4.4 million] in 1996 to 1.8 million [1.4 million–2.4 million] in 2017—the year for which the most recent data are available. However, progress is far slower than that required to reach the 2020 target of fewer than 500 000 new HIV infections
UNICEF  [to 16 Mar 2019]
Selected Press Releases/Reports/Statements
Intensification of fighting impeding humanitarian access and displacing thousands in Hajjah, Yemen
Statement by UNICEF Executive Director Henrietta Fore

Press release
260,000 children suffering from severe acute malnutrition in the Kasai region of the Democratic Republic of the Congo – UNICEF
Humanitarian situation in Kasai remains precarious following recent influx of Congolese families returning from Angola

2018 deadliest year yet for children in Syria as war enters 9th year
Statement by UNICEF Executive Director Henrietta Fore

Vaccine Confidence Project [to 16 Mar 2019]
No new digest content identified.
Vaccine Education Center – Children’s Hospital of Philadelphia [to 16 Mar 2019]
No new digest content identified.
Wellcome Trust [to 16 Mar 2019]
No new digest content identified.

The Wistar Institute [to 16 Mar 2019]
No new digest content identified.

World Organisation for Animal Health (OIE)   [to 16 Mar 2019]
FAO, OIE, and WHO launch a guide for countries on taking a One Health approach to addressing zoonotic diseases
Zoonotic diseases continue to be a threat to global health, causing millions of deaths and economic losses every year. To support countries to control these diseases, the Tripartite organisations (FAO, OIE and WHO) today launched a guide entitled ‘Taking a Multisectoral, One Health Approach: A Tripartite Guide to Addressing Zoonotic Diseases in Countries’.


BIO [to 16 Mar 2019]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Mar 2019]
No new digest content identified.

IFPMA [to 16 Mar 2019]
No new digest content identified.

PhRMA [to 16 Mar 2019]
No new digest content identified.